INTRODUCTION
The risk of cardiovascular disease (CVD) is increased in rheumatoid arthritis (RA) [1] [2] [3] [4] [5] , but no diseasespecific treatment strategies have been agreed on. RA increases CVD morbidity by 1.5 to two-fold compared with the general population [4,6 & ], with recent evidence supporting the notion that the mortality gap between patients with RA and those in the general population has widened [7] . Many factors contribute to the elevated CVD risk in RA, but it cannot be explained by traditional cardiovascular risk factors alone [8] [9] [10] [11] . RA-specific factorsimmune dysregulation, systemic inflammation, plaque instability, impaired coronary reserve, elevated thrombotic markers or specific treatments (i.e. oral glucocorticoids or nonsteroidal anti-inflammatory drugs) -likely also contribute to the increased CVD risk. In addition, extra-articular manifestations of disease are shown to confer an increased likelihood of CVD in patients with RA [12, 13] . Thus, traditional CVD risk factors and RA-specific risk factors must be addressed to improve cardiovascular outcomes.
In this review, we examine whether thresholds for prevention and treatment of traditional cardiovascular risk factors should be altered in patients with RA and how RA-specific treatment modulates CVD risk.
SHOULD THRESHOLDS FOR TREATMENT OF TRADITIONAL CARDIOVASCULAR DISEASE RISK FACTORS BE ALTERED IN PATIENTS WITH RHEUMATOID ARTHRITIS?
Prior studies show that the prevalence of traditional cardiovascular risk factors is increased in patients with RA. Several traditional risk factors, such as dyslipidemia, type 2 diabetes mellitus, hypertension, physical inactivity, advanced age, male sex, family history of CVD, cigarette smoking and altered BMI, predict CVD in patients with RA [14, 15] . As well, hypertension, elevated low-density lipoprotein (LDL) and diabetes mellitus often go untreated or undertreated in this population [16 && ,17 & ,18 ]. Whereas obesity is widely appreciated as a CVD risk factor in the general population and RA, rheumatoid cachexia may also confer an elevated CVD risk in patients with RA [19] . Recent cardiology and rheumatology management guidelines acknowledge the higher risk of CVD in patients with RA [20, 21] , but what remains unclear is whether treatment thresholds in patients with RA should be altered to account for these CVD risk factors. In this section, we examine the elevated risk conferred by various traditional CVD risk factors and provide recommendations regarding management.
Dyslipidemia
Despite the increased risk of CVD in patients with RA, the prevalence of dyslipidemia does not appear to differ significantly between patients with RA and the general population [10] . Lipid levels may be altered by RA disease activity, although the data are conflicting. In early RA, some studies demonstrate decreased levels of total cholesterol (TC) and LDL cholesterol levels [22, 23] , whereas others demonstrate increased levels of TC, LDL and highdensity lipoprotein levels [24, 25] . Although reports of lipid profiles in patients with established RA vary, growing evidence suggests that lower TC and LDL levels result in paradoxically elevated CVD risk in patients with RA [26,27 & ]. The majority of recent studies [28] [29] [30] 31 & ] of lipid profiles in patients with RA show that tumour necrosis factor (TNF) inhibitors and tocilizumab worsen lipid levels. As well, a recent study [32 & ] found that hydroxychloroquine may improve the atherogenic profile.
Statin use in patients with RA has been demonstrated to decrease TC and LDL levels in a randomized placebo-controlled trial [33] . A ] noted that patients with RA discontinuing statin therapy experienced an increased risk of myocardial infarction (MI), although the results of observational 'stopping trials' are difficult to interpret. Observational studies are unlikely to provide all of the answers. To this end, a randomized placebocontrolled study of atorvastatin in approximately 3000 patients with RA is in progress (TRACE RA; http://www.dgoh.nhs.uk/tracera/http://www.dgoh. nhs.uk/tracera/). This study [37] randomized patients with slight elevation in LDL (100-130 mg/dl) to test whether a more aggressive lipid treatment strategy than what is recommended in the general population is warranted.
Until results from this study are available, we recommend annual lipid profile screening and adherence to the current general population guidelines.
Diabetes
Although diabetes mellitus is a clear risk factor for CVD in the general population, its influence on future CVD risk in patients with RA is less clear. Although there are strong epidemiological data supporting an association between RA and insulin resistance [38] , studies [1, 8, 10, 39] including diabetes as a covariate did not find a statistically significant relationship with CVD, although several were underpowered. In the QUEST-RA study [40] , diabetes emerged as an independent risk factor in multivariate analyses but only for stroke. A recent prospective study [41 & ] reported that diabetes mellitus was significantly predictive of a new cardiovascular event in patients with early RA.
Given these conflicting data, at least annual screening of haemoglobin A1c in patients with active disease, chronic corticosteroid use or those at a high risk for CVD seems warranted. Treatment targets for diabetes mellitus should adhere to general population standards.
Hypertension
Studies assessing the prevalence of hypertension in RA do not suggest an increase in risk compared with the general population [42 patients with RA compared with those without [43] . A population-based cohort study [14] evaluating patients with newly diagnosed RA showed that the 10-year absolute risk of a CVD event rose significantly if hypertension was present. A recent multiethnic study [16 && ] of atherosclerosis demonstrated that rates of undiagnosed hypertension are higher in patients with RA compared with a non-RA cohort. Hypertension can be particularly difficult to control in patients with RA using treatment with NSAIDs, chronic corticosteroids or diseasemodifying anti-rheumatic drugs (DMARDs) associated with increased blood pressure (i.e. leflunomide and cyclosporine) [44] [45] [46] .
Given these findings, it is important to regularly monitor blood pressure levels and treat on the basis of general population guidelines for hypertension.
Cigarette smoking
Cigarette smoking is considered one of the strongest environmental risk factors for RA incidence and progression, particularly in genetically predisposed individuals [47] . In patients with RA, cigarette smoking is associated with anticitrullinated peptide antibody production and increases the risk of joint erosions and extra-articular manifestations [48] . In seropositive RA men, cigarette smoking is associated with increased disease severity [49] . However, in a population-based incidence cohort of individuals with RA, cigarette smoking imparted less risk for the development of CVD in patients with RA compared with the non-RA group [10] .
Smoking cessation should be emphasized in patients with RA, particularly to improve disease activity but also given the probable CVD benefit.
BMI
Although obesity is a well documented traditional CVD risk factor in the population, low BMI is also shown to be associated with an increased risk of death due to CVD in patients with RA [19, 50] . Although it remains unclear whether individuals with RA have an elevated BMI compared with the general population [51] , obese patients with RA tend to have worse disease activity and a significantly elevated CVD risk [52, 53] . Rheumatoid cachexia may be equally important [54] , although a recent small, observational, prospective study [41 & ] did not demonstrate low BMI to be a significant predictor of new cardiovascular events.
Given the elevated CVD risk, regular monitoring of BMI and encouragement of healthy diet and regular exercise for patients with RA is likely to be of significant CVD benefit.
DOES TREATMENT OF RHEUMATOID ARTHRITIS MODULATE CARDIOVASCULAR RISK?
On the basis of the accumulating evidence of an increased association of systemic inflammation with increased CVD risk [41 & ,55-57,58 & ,59,60 & ,61], the implication is that better control of disease activity in patients with RA will result in improved CVD outcomes. However, it is not currently known whether the relationship between systemic inflammation and CVD risk is causal or simply an association. To date, no randomized controlled trial has directly evaluated whether anti-inflammatory agents reduce CVD event rates, in either RA or the general population. Although a number of studies have evaluated the effects of whether effective treatment of RA improves cardiovascular outcome, these studies are conflicted and are unfortunately limited by study design and a low number of events. In this section, we attempt to highlight the most recent literature focusing on how individual treatment options may specifically modulate active inflammation and CVD risk factors in patients with RA.
NSAIDs
The relationship of NSAIDs to cardiovascular morbidity and mortality in patients with RA remains controversial. Several earlier clinical trials demonstrated a higher risk of adverse CVD outcomes for patients treated with selective cyclooxygenase-2 (COX2) inhibitors than placebo [62] [63] [64] [65] . Epidemiological studies [66] [67] [68] of CVD outcomes in large population-based groups have also suggested increased toxicity of nonselective NSAIDs. Subgroup analyses demonstrated that factors such as age more than 80 years, hypertension, prior cardiovascular events, presence of RA or chronic obstructive pulmonary disease (COPD) may identify patients at a high risk [69] . However, few data exist regarding the CVD safety of NSAID use in cohorts of patients with chronic inflammatory disease. A previous meta-analysis of nine randomized controlled trials in patients with osteoarthritis and RA found that use of nonselective NSAIDs, compared with placebo, had no significant effect on CVD events in these patients [70] . Similar results from a primary carebased inception cohort of patients with inflammatory polyarthritis showed that NSAID use does not appear to be associated with increased CVD or allcause mortality [71] . Although there are conflicting data regarding these agents' safety in RA, one should employ similar caution regarding use of NSAIDs in patients with RA as with the general population.
Corticosteroids
Corticosteroid studies demonstrate contradictory results regarding their impact on CVD risk. Previous studies demonstrate considerable detrimental effects of corticosteroids on blood pressure, insulin resistance, hypertension, body weight and fat distribution [72] [73] [74] . This risk appears dose-dependent, given that the use of corticosteroids in high cumulative doses has been associated with increased CVD mortality, MI and heart failure [75] . Although previous studies suggest an adverse impact on lipid profiles, corticosteroids may also have cardioprotective effects mediated by their anti-inflammatory effects. Corticosteroids may actually improve the lipid profile by increasing HDL levels and lowering the TC to HDL ratio [76] [77] [78] . Furthermore, a recent systematic literature review assessing the CVD risk in patients with RA using low-dose corticosteroids (defined as <10 mg/day of prednisone) demonstrated weak association with CVD risk factors.
However, a trend of increasing major cardiovascular events was identified [79 & ]. An RA cohort study [80 & ] further demonstrated that even at daily dosages of less than 10 mg of prednisone equivalents, glucocorticoids appear associated with excess cardiovascular risk.
Given the concerns raised, we suggest that corticosteroid dosing be limited to the shortest duration possible. ( Fig. 1) . The evidence for benefit is strongest for a reduction in the overall CVD morbidity and mortality and weakest for stroke outcomes. A large randomized, double-blind, placebo-controlled trial known as CIRT (Cardiovascular Inflammation Reduction Trial) is currently funded by the National Institute of Health (NIH) to assess the effect of MTX (15-20 mg weekly) in the secondary prevention of MI, stroke and cardiovascular death among patients with known prior CVD who have diabetes mellitus or metabolic syndrome [87] . The potential impact of CIRT is significant in that if MTX is shown to improve CVD outcomes, this would not only lend support to the hypothesis of the significant role of inflammation in the development of CVD but would also provide a novel treatment for patients with chronic CVD. Until results from the CIRT are known, we recommend continuing MTX as a DMARD in patients with RA, but cannot definitively comment on its CVD benefits.
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Tumour necrosis factor inhibitors
TNF-a is an inflammatory cytokine known to contribute to the pathogenesis of RA and has an atherogenic effect on the endothelial cells lining arterial walls [88]; it may contribute to vascular instability and atherosclerosis progression [89] . As a result, TNF inhibitor therapy has been postulated to have a potential cardioprotective effect. In patients with RA, recent epidemiological studies have shown conflicting results. Data , with recent literature suggesting that these agents are associated with significant increases of TC, HDL and triglyceride levels, although LDL levels and the atherogenic index again remained unaffected [96 & ]. Therefore, the presumed cardioprotective effects of TNF inhibitors in patients with RA do not seem to be explained by changes in the lipid profile, given that long-term treatment appears to have no effect on the atherogenic index or LDL levels. Although increased HDL levels may offer benefit towards improved CVD outcomes, this has yet to be confirmed by prospective studies with long-term follow-up.
Among patients with RA, we recommend continuing use of TNF-inhibitors as DMARD therapy, with annual lipid screening and management based on current general population guidelines.
Nontumour necrosis factor biologic diseasemodifying anti-rheumatic drugs
Newer agents in RA treatment demonstrate conflicting results regarding CVD risk. Long-term safety analysis of rituximab, a human-murine chimeric mAb against CD20 approved for the treatment of refractory RA, demonstrated no notable differences in serious CVD events during placebo-controlled periods [97, 98] . Recent studies [99, 100] evaluating the effect of rituximab on the lipid profile and endothelial dysfunction have shown conflicting results. Tocilizumab, a humanized mAb against the interleukin-6 receptor, has been associated with CRP reductions within 2 weeks of initiation of treatment [101] . However, studies on tocilizumab demonstrate an adverse impact on lipid profiles [ ]. Larger studies, with long-term follow-up, are needed to determine the relationship between these newer agents and the risk of CVD. It is possible that they will have beneficial effects on CVD risk, but more data need to be collected to understand the CVD risk-benefit profile of these agents.
CONCLUSION
We have focused on treatment effects on CVD in patients with RA. However, targeting preventive treatments requires accurate estimation of CVD risk. Multiple studies demonstrate the limitations of general population CVD risk stratification methods among patients with RA [106 && ,107,108 & ], and this remains an active area of investigation. Future research is needed to develop and validate RA-specific CVD risk algorithms to provide effective primary and secondary prevention in patients with RA.
We suggest that clinicians maintain a high level of suspicion for CVD and its risk factors in RA. Until treatment trials have been completed, regular screening for traditional CVD risk factors, education of patients and primary care providers and aggressive management of each risk factor is prudent. Treating to target with an aggressive DMARD strategy may also lead to reduced CVD risk. However, this is still an unproven hypothesis.
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